FDA 483 - Edge Pharma, LLC - August 20, 2014

An FDA inspection conducted at Edge Pharmacy Services, LLC, an outsourcing facility in Colchester, VT, from July 22 to August 20, 2014, revealed critical deficiencies in its manufacturing and quality control processes. The FDA Form 483 outlined significant non-compliance related to sterile drug production. Key violations included inadequate validation of sterilization procedures, specifically regarding airflow patterns under dynamic conditions and the bacterial retention capabilities of filters. The company routinely released sterile drug products without validating sterility test methods or establishing bioburden limits for bulk solutions. Many products were distributed before final sterility test results were available, often lacking proper documentation. Environmental monitoring in aseptic processing areas was deficient, with infrequent recording of air pressure differentials during active use. The firm failed to routinely test finished sterile drug products for the identity and strength of active ingredients prior to release. Additionally, component testing was inadequate, as the company did not confirm the reliability of supplier certificates of analysis or perform identity tests on incoming raw materials. Finally, numerous drug product labels lacked essential information mandated by Section 503B(a)(10) of the Food, Drug, and Cosmetic Act, such as statements identifying the product as compounded, complete ingredient lists, adverse event reporting details, and storage instructions. Edge Pharmacy Services, LLC is required to address these systemic issues to ensure the safety, quality, and efficacy of its compounded sterile drug products, aligning operations with current Good Manufacturing Practices (cGMP) and federal labeling requirements for outsourcing facilities.